Navigation Links
ForteBio Launches New Biosensor for Kinetic Analysis and Screening of Human IgG Antibodies
Date:3/3/2009

MENLO PARK, Calif., March 3 /PRNewswire/ -- ForteBio(R), Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its Anti-Human IgG Fc Capture (AHC) biosensor for use on the company's Octet(R) instrumentation platform. The new biosensor enables more cost-effective, easy-to-use and rapid kinetic characterization and screening of human IgG antibodies and other Fc-containing proteins - important components in biomolecular therapeutic development - and further broadens the menu of Octet system applications.

"Researchers in bioprocessing and cell line development who study kinetic characterization of human IgG antibodies and other proteins can now benefit from the efficiencies of ForteBio's Octet platform, which enables high-throughput, real-time, label-free detection and screening," said Christopher Silva, ForteBio's vice president of marketing. "The innovative, new AHC biosensor enables off-the-shelf, capture-based kinetics of human IgGs or other Fc-containing proteins without the need to biotinylate. It is also designed for use in buffer or crude supernatants, and can be regenerated and reused for increased cost-efficiency."

The new AHC biosensor leverages the Octet platform's proprietary Bio-Layer Interferometry technology to enable kinetic profiling of human IgGs against analyte in a microplate well format. The biosensor surface can also be used to conduct ligand inhibition assays by expanding the variables that can be measured, such as blocking and unblocking analytes, affinity, and association and dissociation rates. The new AHC biosensor further expands the capabilities of the Octet platform which already supports quantitation of human IgG using Protein A.

ForteBio's Octet biosensors are configured in a standard 96-well format. Its biosensors simplify quantitation and kinetic characterization by eliminating throughput limitations of traditional SPR-based systems. Octet biosensors are coated with a proprietary biocompatible matrix that is uniform, non-denaturing and has minimal non-specific binding.

About ForteBio, Inc.

ForteBio is a venture-capital funded life science company providing analytical systems to accelerate biotherapeutic drug development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio's analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California, with wholly owned subsidiaries in London and Shanghai. For more information, visit www.fortebio.com.


'/>"/>
SOURCE ForteBio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Halo Pharmaceutical Launches a Branded Product Marketing Company in Canada
2. A.L.L. Launches Stop Sebelius Campaign
3. Operation Rescue Launches Opposition to Gov. Sebelius Confirmation as HHS Secretary
4. DaVita Launches Nationwide Events in Honor of National Kidney Month
5. Silverstone Solutions Launches New Version of Kidney Paired Donation Software at DEMO 2009
6. CheckOrphan Launches iWish to Commemorate Rare Disease Day
7. Inspired Cancer Survivor Launches Customized Hair Replacement Techniques at Award-Winning Hair Salon
8. Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics
9. Select Comfort Launches Entirely Redesigned Line Of Sleep Number Beds
10. Talk About Curing Autism Launches Seven New Chapters
11. The Organic Institute Launches Organic. Its Worth It.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... With the opioid epidemic now ... excessive levels of alcohol use. Alcohol and its misuse causes long-term consequences for ... the susceptibility to strokes in those 65 years and older. In addition, there ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ... process that selects DNA or RNA from a random library of sequences depending ... used as drugs or diagnostic agents. SELEX selection is commonly performed using filters, ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... ... hired award-winning creative director Joe Ferrazano to serve in the newly created position ... will be overseeing the agency’s creative efforts in the Chicago and LA offices. ...
(Date:5/3/2016)... ... ... Elizabeth Murray has always loved walking one to two miles a day. ... and one on her arm. But she got to the point where she could ... , The valves of the heart wouldn’t close properly resulting in mitral regurgitation, where ...
(Date:5/3/2016)... ... May 03, 2016 , ... Excessive panting in the car ... anxiety. "Pet owners often think anxiety only manifests itself as trembling or ‘tail ... ways, and there’s things that be done about it,” says Dr. Jim Lowe, technical ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... 2016 Norgine B.V. ... einen entscheidenden Meilenstein durch diese Veröffentlichung zur  ... Handeln, um Patientenresultate  bei Verdauungs- und Lebererkrankungen ... im Verständnis der Hepatischen Enzephalopathie bei und ... Hepatische Enzephalopathie in der Öffentlichkeit zu schaffen ...
(Date:5/2/2016)... Leading Economies with Fastest Real GDP Annual Percentage Change, 2015  ... India 7.3, , Source: IMF and TechSci Research   ... Brazil , Russia , India ... registered the fastest GDP growth during the first decade of the 21 st ... Brazil and Russia , along with ...
(Date:5/2/2016)... 2, 2016  While nearly three-quarters of Americans (71%) ... on their health, only about half report taking any ... results of a new survey announced today by Hologic ... of National Osteoporosis Month, Hologic is raising awareness of ... 56 million Americans. Osteoporosis is a disease ...
Breaking Medicine Technology: